Mutual of America Capital Management LLC Decreases Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Mutual of America Capital Management LLC lowered its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 4.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 31,935 shares of the specialty pharmaceutical company’s stock after selling 1,442 shares during the period. Mutual of America Capital Management LLC’s holdings in Jazz Pharmaceuticals were worth $3,933,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in JAZZ. IFP Advisors Inc purchased a new position in shares of Jazz Pharmaceuticals during the fourth quarter worth $25,000. UMB Bank n.a. raised its holdings in shares of Jazz Pharmaceuticals by 70.9% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after purchasing an additional 129 shares during the last quarter. Itau Unibanco Holding S.A. raised its holdings in shares of Jazz Pharmaceuticals by 63.2% during the third quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock worth $49,000 after purchasing an additional 172 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Jazz Pharmaceuticals by 49.8% during the fourth quarter. GAMMA Investing LLC now owns 620 shares of the specialty pharmaceutical company’s stock worth $76,000 after purchasing an additional 206 shares during the last quarter. Finally, Venturi Wealth Management LLC raised its holdings in shares of Jazz Pharmaceuticals by 577.0% during the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after purchasing an additional 704 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. TD Cowen reduced their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. JPMorgan Chase & Co. raised their price target on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Morgan Stanley upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $140.00 to $175.00 in a research report on Thursday, December 12th. Finally, Piper Sandler restated an “overweight” rating and set a $176.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $182.47.

Insider Activity

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the transaction, the chief executive officer now directly owns 425,525 shares in the company, valued at approximately $52,522,550.75. The trade was a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Neena M. Patil sold 3,800 shares of the business’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $144.87, for a total transaction of $550,506.00. Following the transaction, the executive vice president now owns 33,318 shares in the company, valued at $4,826,778.66. The trade was a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 18,113 shares of company stock worth $2,551,834 over the last 90 days. 4.20% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Stock Up 0.9 %

Shares of NASDAQ JAZZ opened at $140.23 on Thursday. The company’s 50-day simple moving average is $127.64 and its 200-day simple moving average is $119.71. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $148.06. The firm has a market cap of $8.52 billion, a price-to-earnings ratio of 19.75, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.